Wen-Jie Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wen-Jie Tang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Dan Li
Digestive Department, Union Hospital of Fujian Medical University , Fuzhou 350001, China
1 shared publication- Jian Ding
Department of Gastroenterology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, People’s Republic of China
1 shared publication - Kai Wang
Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China
1 shared publication - Xiaofei Liang
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, No. 25/Ln 2200 Xie Tu Road, Shanghai, 200032, China
1 shared publication Ying Lu
Research Centre for Translational Medicine, East Hospital, Tongji University School of Medicine , 150 Jimo Road, Shanghai 200120, China
1 shared publicationYou-Zhen Wei
Research Centre for Translational Medicine, East Hospital, Tongji University School of Medicine , 150 Jimo Road, Shanghai 200120, China
1 shared publication
Latest Publications
- Open Access
- 31 August 2016
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 88 (18) , 8997-9003
Construction of Epidermal Growth Factor Receptor Peptide Magnetic Nanovesicles with Lipid Bilayers for Enhanced Capture of Liver Cancer Circulating Tumor Cells
Highly effective targeted tumor recognition via vectors is crucial for cancer detection. In contrast to antibodies and proteins, peptides are direct targeting ligands with a low molecular weight. In the present study, a peptide magnetic nanovector platform containing a lipid bilayer was designed using a peptide amphiphile (PA) as a skeleton material in a controlled manner without surface modification. Fluorescein isothiocyanate-labeled epidermal growth factor receptor (EGFR) peptide nanoparticles (NPs) could specifically bind to EGFR-positive liver tumor cells. EGFR peptide magnetic vesicles (EPMVs) could efficiently recognize and separate hepatoma carcinoma cells from cell solutions and treated blood samples (ratio of magnetic EPMVs versus anti-EpCAM NPs: 3.5 ± 0.29). Analysis of the circulating tumor cell (CTC) count in blood samples from 32 patients with liver cancer showed that EPMVs could be effectively applied for CTC capture. Thus, this nanoscale, targeted cargo-packaging technology may be useful for designing cancer diagnostic systems.
- 31 August 2016
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 88 (18) , 8997-9003
Open AccessConstruction of Epidermal Growth Factor Receptor Peptide Magnetic Nanovesicles with Lipid Bilayers for Enhanced Capture of Liver Cancer Circulating Tumor Cells
Highly effective targeted tumor recognition via vectors is crucial for cancer detection. In contrast to antibodies and proteins, peptides are direct targeting ligands with a low molecular weight. In the present study, a peptide magnetic nanovector platform containing a lipid bilayer was designed using a peptide amphiphile (PA) as a skeleton material in a controlled manner without surface modification. Fluorescein isothiocyanate-labeled epidermal growth factor receptor (EGFR) peptide nanoparticles (NPs) could specifically bind to EGFR-positive liver tumor cells. EGFR peptide magnetic vesicles (EPMVs) could efficiently recognize and separate hepatoma carcinoma cells from cell solutions and treated blood samples (ratio of magnetic EPMVs versus anti-EpCAM NPs: 3.5 ± 0.29). Analysis of the circulating tumor cell (CTC) count in blood samples from 32 patients with liver cancer showed that EPMVs could be effectively applied for CTC capture. Thus, this nanoscale, targeted cargo-packaging technology may be useful for designing cancer diagnostic systems.